SANDOZ DICLOFENAC MISOPROSTOL TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

DICLOFENAC SODIUM; MISOPROSTOL

থেকে পাওয়া:

SANDOZ CANADA INCORPORATED

এটিসি কোড:

M01AB55

INN (আন্তর্জাতিক নাম):

DICLOFENAC, COMBINATIONS

ডোজ:

50MG; 200MCG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

DICLOFENAC SODIUM 50MG; MISOPROSTOL 200MCG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

100/250/500

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0222885003; AHFS:

অনুমোদন অবস্থা:

CANCELLED PRE MARKET

অনুমোদন তারিখ:

2021-04-21

পণ্য বৈশিষ্ট্য

_ _
_Sandoz DiclofenacMisoprostol _
_Page 1 of 48_
PRODUCT MONOGRAPH
Pr
SANDOZ DICLOFENAC MISOPROSTOL
Diclofenac Sodium and Misoprostol Enteric-Coated Tablets
50 mg diclofenac sodium / 200 mcg misoprostol
75 mg diclofenac sodium / 200 mcg misoprostol
NSAID with a Mucosal Protective Agent
Sandoz Canada Inc.
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
Date of Revision:
March 19, 2015
Control no.: 182760
_ _
_Sandoz DiclofenacMisoprostol _
_Page 2 of 48_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY
PRODUCT
INFORMATION
.................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
4
WARNINGS
AND
PRECAUTIONS
..........................................................................................
5
ADVERSE
REACTIONS
..........................................................................................................
15
DRUG
INTERACTIONS
...........................................................................................................
18
DOSAGE
AND
ADMINISTRATION
.......................................................................................
22
OVERDOSAGE
.........................................................................................................................
23
ACTION
AND
CLINICAL
PHARMACOLOGY
.....................................................................
24
STORAGE
AND
STABILITY...................................................................................................
26
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ...................................................... 26
PART II: SCIENTIFIC INFORMATION
................................................................................
28
PHARMACEUTICAL
INFORMATION
........